101 Mission Street
13 articles with PellePharm
PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
Randomized, 12-Month, Pivotal Trial Evaluating the Safety and Efficacy of Patidegib Topical Gel to Reduce the Disease Burden of Chronic BCCs in Patients with Rare Form of Skin Cancer
Phyton Biotech Partners with PellePharm to Develop Renewable Supply of Cyclopamine for Investigational Topical Cancer Therapy
Phyton Biotech and PellePharm today announced an exclusive partnership to develop a plant cell culture-based process to enable the future renewable production of the raw material for PellePharm’s patidegib, an investigational topical therapy for Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC)
Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Piper Jaffray Healthcare Conference on Tuesday, November 27, at 12:30 p.m. EST in New York.
LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases
LEO Pharma A/S acquires minority stake in PellePharm and provides additional non-dilutive capital to fund PellePharm development programs; obtains option to acquire all shares in PellePharm
11/20/2018Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer.
PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and in Patients with Non-Gorlin Sporadic BCCs
PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare skin conditions at their source, today presented updated clinical data from two Phase 2 studies of patidegib topical gel in a poster session at NORD’s Rare Diseases and Orphan Products Breakthrough Summit 2018 in Washington, D.C.
PellePharm today announced that Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, at 4:35 p.m. ET in New York.
PellePharm today announced that the company is scheduled to participate in the Cantor Fitzgerald Dermatology and Aesthetics Summit.
Dr. Ravindran brings more than 15 years of strategic and operational biopharma experience to PellePharm.
The new hires will join current CEO-in-residence, Shafique Virani, M.D., who is focused on central nervous system and oncology development programs.
PellePharm is aiming to launch Phase III trials of the topical hedgehog inhibitor in early 2018.
PellePharm, Inc Announces Topline Results From Phase II Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing
PellePharm, Inc Launches With Financing From BridgeBio Pharma To Develop Topical Therapy For Basal Cell Carcinomas And Gorlin Syndrome